Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at Citizens Jmp

Research analysts at Citizens Jmp started coverage on shares of Rapport Therapeutics (NASDAQ:RAPP) in a report released on Tuesday. The firm set a “mkt outperform” rating on the stock.

Rapport Therapeutics Trading Down 1.2 %

NASDAQ:RAPP traded down $0.12 on Tuesday, hitting $9.39. 22,908 shares of the stock were exchanged, compared to its average volume of 179,012. The stock has a fifty day moving average of $12.04 and a 200-day moving average of $17.56. The stock has a market cap of $342.81 million and a PE ratio of -0.68. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $29.74.

Insider Activity at Rapport Therapeutics

In other news, CFO Troy A. Ignelzi acquired 9,900 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were bought at an average price of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the purchase, the chief financial officer now directly owns 9,900 shares of the company’s stock, valued at approximately $99,990. This trade represents a ? increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Wendy B. Young acquired 6,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was purchased at an average price of $10.21 per share, for a total transaction of $61,260.00. Following the acquisition, the director now directly owns 6,000 shares in the company, valued at $61,260. This represents a ? increase in their ownership of the stock. The disclosure for this purchase can be found here.

Hedge Funds Weigh In On Rapport Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in RAPP. GAMMA Investing LLC increased its stake in shares of Rapport Therapeutics by 91,980.0% in the first quarter. GAMMA Investing LLC now owns 9,208 shares of the company’s stock worth $918,000 after buying an additional 9,198 shares during the last quarter. California State Teachers Retirement System increased its position in shares of Rapport Therapeutics by 1,151.2% in the 4th quarter. California State Teachers Retirement System now owns 8,571 shares of the company’s stock worth $152,000 after purchasing an additional 7,886 shares during the last quarter. Deutsche Bank AG acquired a new stake in shares of Rapport Therapeutics in the 4th quarter valued at about $41,000. Crestline Management LP bought a new position in shares of Rapport Therapeutics during the fourth quarter worth about $488,000. Finally, Virtus ETF Advisers LLC bought a new stake in Rapport Therapeutics in the fourth quarter valued at about $66,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.